Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria

Research in Social and Administrative Pharmacy

Volumn 10, Issue 1, 2014, Pages 106-125

  Wang, Junling ^a   Qiao, Yanru ^a   Tina Shih, Ya Chen ^b   Wan, Jim Y ^c   White Means, Shelley I ^a   Dagogo Jack, Samuel ^c   Cushman, William C ^c,d,e  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Eligibility criteria; Ethnicity; Health disparities; Medication therapy management services; Race

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; ELIGIBILITY CRITERIA; ETHNIC GROUP; ETHNICITY; FEMALE; HEALTH DISPARITY; HEALTH SERVICE; HISPANIC; HUMAN; MALE; MEDICARE; MEDICATION THERAPY MANAGEMENT; MEDICATION THERAPY MANAGEMENT SERVICES; MULTIVARIATE ANALYSIS; ORGANIZATION AND MANAGEMENT; RACE; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; UNITED STATES; UTILIZATION REVIEW; VERY ELDERLY;

ELIGIBILITY CRITERIA; ETHNICITY; HEALTH DISPARITIES; MEDICATION THERAPY MANAGEMENT SERVICES; RACE;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ELIGIBILITY DETERMINATION; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; MEDICATION THERAPY MANAGEMENT; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84888869815     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2013.03.007     Document Type: Article

References (48)

1. Medicare program; Medicare prescription drug benefit. Final rule. Fed Regist 2005, 70:4193-4585. Centers for Medicare & Medicaid Services. Department of Health and Human Services.
2. Bluml B.M. Definition of medication therapy management: development of professionwide consensus. J Am Pharm Assoc 2005, 45:566-572.
3. Medication therapy management in community pharmacy practice: core elements of an MTM service (Version 1.0). J Am Pharm Assoc (2003) 2005, 45:573-579. American Pharmacists Association and National Association of Chain Drug Stores Foundation.
4. Medicare Part D Medication Therapy Management (MTM) Programs, Centers for Medicare and Medicaid Services, U.S 2011, Department of Health and Human Services, Available at:, Accessed 21.12.12. http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/MTMFactSheet2011063011Final.pdf.
5. Daniel G.W., Malone D.C. Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. J Manag Care Pharm 2007, 13:142-154.
6. Carter B.L., Malone D.C., Billups S.J., et al. Interpreting the findings of the IMPROVE study. Am J Health Syst Pharm 2001, 58:1330-1337. Impact of Managed Pharmaceutical care on resource utilization and Outcomes in Veterans affairs medical centers.
7. Ellis S.L., Carter B.L., Malone D.C., et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000, 20:1508-1516.
8. Fera T., Bluml B.M., Ellis W.M. Diabetes Ten City Challenge: final economic and clinical results. J Am Pharm Assoc 2009, 49:383-391.
9. Wang J., Mullins C.D., Brown L.M., et al. Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res 2010, 45:1061-1082.
10. Medicare Part D Medication Therapy Management (MTM) Programs, Centers for Medicare and Medicaid Services, U.S 2010, Department of Health and Human Services, Available at:, Accessed 22.12.12. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9525.
11. Byrd L., Fletcher A., Menifield C. Disparities in health care: minority elders at risk. ABNF J 2007, 18:51-55.
12. Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care 2002, National Academy Press, Washington, DC. B.D. Smedley, A.Y. Stith, A.R. Nelson (Eds.).
13. Wang J., Brown L.M., Hong S.H. Racial and ethnic disparities in meeting MTM eligibility criteria among the non-Medicare Population. J Am Pharm Assoc (2003) 2012, 52:e87-e96.
14. Wang J., Qiao Y. Historical trend of disparity implications of Medicare MTM eligibility criteria. Res Soc Adm Pharm 2012, Epub ahead of print.
15. Wang J., Zuckerman I.H., Miller N.A., Shaya F.T., Noel J.M., Mullins C.D. Accessing new prescription drugs: disparities among non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Health Serv Res 2007, 42:1499-1519.
16. Wang J., Noel J.M., Zuckerman I.H., Miller N.A., Shaya F.T., Mullins C.D. Disparities in access to essential new prescription drugs between non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Med Care Res Rev 2006, 63:742-763.
17. Wang J., White-Means S.I., Hufstader M.A., Walker G.D. The economic implications of the racial and ethnic disparities in the use of selective serotonin reuptake inhibitors. Curr Med Res Opin 2007, 23:853-863.
18. Briesacher B., Limcangco R., Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ R 2003, 25:63-76.
19. Schore J., Brown R., Lavin B. Racial disparities in prescription drug use among dually eligible beneficiaries. Health Care Financ R 2003, 25:77-90.
20. Lee J.K., Grace K.A., Taylor A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006, 296:2563-2571.
21. Clifford R.M., Davis W.A., Batty K.T., Davis T.M. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle diabetes study. Diabetes Care 2005, 28:771-776.
22. Schnipper J.L., Kirwin J.L., Cotugno M.C., et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 2006, 166:565-571.
23. Cranor C.W., Bunting B.A., Christensen D.B. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 2003, 43:173-184.
24. Bunting B.A., Smith B.H., Sutherland S.E. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc (2003) 2008, 48:23-31.
25. McMullin S.T., Hennenfent J.A., Ritchie D.J., et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med 1999, 159:2306-2309.
26. Etemad L.R., Hay J.W. Cost-effectiveness analysis of pharmaceutical care in a Medicare drug benefit program. Value Health 2003, 6:425-435.
27. Compilation of Patient Protection and Affordable Care Act, the Office of the Legislative Counsel for the U.S. House of Representatives. Available at: Accessed 22.12.12. http://docs.house.gov/energycommerce/ppacacon.pdf.
28. Wang J., Mullins C.D., Chang C.F., et al. Comparison of changes over time in health expenditures per capita across racial and ethnic groups. Int J Public Policy 2010, 6:172-189.
29. Gerber B.S., Cho Y.I., Arozullah A.M., Lee S.Y. Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother 2010, 8:136-145.
30. Shi L., Green L.H., Kazakova S. Primary care experience and racial disparities in self-reported health status. J Am Board Fam Pract 2004, 17:443-452.
31. Ciol M.A., Shumway-Cook A., Hoffman J.M., Yorkston K.M., Dudgeon B.J., Chan L. Minority disparities in disability between Medicare beneficiaries. J Am Geriatr Soc 2008, 56:444-453.
32. Andersen R., Rice T., Kominski G. Changing the U.S. Health Care System: Key Issues in Health Services, Policy and Management 2007, Jossey-Bass, San Francisco, CA. 3rd ed.
33. Iezzoni L.I. Risk Adjustment for Measuring Health Outcomes 1997, Health Administration Press, Chicago, IL. 2nd ed.
34. Medicare Current Beneficiary Survey. Centers for Medicare & Medicaid Services. Available at: Accessed 22.12.12. http://www.cms.hhs.gov/MCBS/.
35. Electronic Orange Book (EOB) Query Data Files, theFood and Drug Administration. Available at: Accessed 22.12.12. http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm.
36. Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS), 2008. U.S. Agency for Healthcare Research and Quality. Available at: Accessed 22.12.12. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
37. Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality. Available at: Accessed 22.12.12. http://www.meps.ahrq.gov/mepsweb/.
38. Technical Specifications for PQA Approved Measures 2012, Pharmacy Quality Alliance.
39. Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163:2716-2724.
40. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012, 60:616-631. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel.
41. Consumer Price Index. Bureau of Labor Statistics, Department of Labor. Available at: Accessed 22.12.12. http://www.bls.gov/cpi/.
42. Buis M. Stata tip 87: Interpretation of interactions in non-linear models. Stata J 2010, 305-308. Available at:, Accessed 04.02.13. http://www.maartenbuis.nl/publications/intera-ctions.pdf.
43. Healthy People 2010 Final Review. Centers for Disease Control and Prevention. Available at: Accessed 22.12.12. http://www.cdc.gov/nchs/data/hpdata2010/hp2010_final_review_executive_summary.pdf.
44. Ho K., Moy K., Clancy C.M. Can incentives to improve quality reduce disparities?. Health Serv Res 2010, 45:1-5.
45. Ryan A.M. Has pay-for-performance decreased access for minority patients?. Health Serv Res 2010, 45:6-23.
46. Medicare advantage 2012 Data Spotlight: Enrollment Market Update. Gold M, Jacobson G, Damico A, Neuman T. The Henry J. Kaiser Family Foundation. Available at: Accessed 22.12.12. http://www.kff.org/medicare/upload/8323.pdf.
47. Chen J., Rizzo J.A., Ortega A.N. Racial and ethnic differences in drug expenditures and access under Medicare Part D. J Health Care Poor Underserved 2011, 22:1059-1074.
48. Sassi F., Le Grand J., Archard L. Equity versus efficiency: a dilemma for the NHS. If the NHS is serious about equity it must offer guidance when principles conflict. BMJ 2001, 323:762-763.